2 episodes
Cholesterol Conversations North American Thrombosis Forum
-
- Health & Fitness
Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone.
NATF is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.
-
How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals
In this episode of Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations.
-
ASCVD Management: Making the Case for Nonstatin Therapies
In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for patients who don’t respond to statin therapy alone.